Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...

Equities research analysts at William Blair lowered their FY2025 earnings per share estimates for shares of Zealand Pharma A/S in a research note issued to investors on Wednesday, March 12th. William ...

Shares of weight loss drug developers gained on Wednesday after Roche (OTCQX:RHHBF) announced a multi-billion-dollar deal ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

SEB Equities upgraded Zealand Pharma (ZLDPF) to Buy from Hold with an DKK 850 price target Light Up your Portfolio with Spark:Easily identify ...

Zealand Pharma AS (ZLDPF) reported significant clinical advancements in their obesity pipeline, particularly with petrelintide and survodutide. The company has a strong cash position of DKK9 ...

Stay updated on market trends for ZLDPF. Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names The $200B GLP-1 market ...

Welcome to the Zealand Pharma Results for Full Year 2024 Conference Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today Anna Krassowska, Head of ...

OTCMKTS:ZLDPF opened at $104.01 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 35.49 and a current ratio of 35.49. Zealand Pharma A/S has a 52-week low of $67.58 and a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...